It is referred to as a focused therapy mainly because it exclusively targets the CD38  which can be overexpressed on the multiple myeloma cells. Daratumumab is from a class of medicines named CD38 monoclonal antibodies.  These are typically biological items that have presently been approved via the FDA, versus which biosimilar solutions are in